Published online Sep 15, 2020. doi: 10.4251/wjgo.v12.i9.1056
Peer-review started: April 15, 2020
First decision: July 5, 2020
Revised: July 18, 2020
Accepted: August 1, 2020
Article in press: August 1, 2020
Published online: September 15, 2020
Processing time: 147 Days and 18.2 Hours
Pancreatic cystic lesions (PCLs) constitute a clinical dilemma due to indeterminate risk of malignancy. Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms are cystic precursors of pancreatic ductal adenocarcinoma (PDAC), possibly allowing early diagnosis. Somatic mutations in GNAS are characteristic of IPMNs, but their role in carcinogenesis is unclear. GNAS is a complex imprinted locus that encodes the α-subunit of the stimulatory heterotrimeric G protein (Gsα), an ubiquitous signaling protein. This locus encodes four monoallelic (NESP55, AS, XL, 1A) and one biallelic (Gsα) transcript(s), due to differentially methylated regions (DMRs) in paternal and maternal alleles, denominated imprinting. Paternal methylation of NESP55 and maternal methylation of AS, XL, and 1A lead, respectively, to maternal and paternal allele expressions, with Gsα biallelically expressed in most tissues, due to absent methylation.
GNAS somatic mutations are characteristic of IPMNs, although epigenetic alterations in the GNAS locus have not been previously evaluated in PCLs. Methylation of DMRs at the GNAS locus may occur at the somatic level and modulate Gsα expression.
In this study, we evaluate if methylation changes in DMRs at the GNAS locus could contribute to tumor progression of PCLs.
We performed a longitudinal cohort study of PCLs with GNAS locus methylation analysis performed in PCF samples obtained by endoscopic ultrasound with fine needle aspiration.
Fifty-two PCF samples obtained by endoscopic ultrasound with fine needle aspiration and previously characterized for KRAS and GNAS mutations were studied. The final diagnoses were surgical (11) and clinicopathological (41), including 30 benign cysts, 14 pre-malignant cyst, and eight malignant cysts. Methylation changes at NESP55, GNASAS, GNAS1A, and especially GNASXL were more frequent in malignant cysts and were useful for their diagnosis. A combined variable defined as “GNAS locus methylation changes” was significantly associated with malignancy (6/8 malignant cysts and only 2/20 benign cysts) and improved classification. Hypermethylation in both maternally (NESP55) and paternally (GNASXL) derived promoters was found in 3/3 PDACs.
This is the first study to identify methylation changes in the GNAS locus that improved the diagnosis of malignant PCs and suggest a role in progression to PDAC.
Although the small sample size and lack of validation in an independent sample are significant limits regarding the present study, our pilot data may be the basis for exploring GNAS methylation in larger, well-characterized sets of samples. As methylation status may impact gene expression, additional evaluation of GNAS transcripts in PCF may elucidate their function in pancreatic cystic neoplasms.